Shaanxi Meibang Pharmaceutical Group (605033) Fair Value & Analysis
Basic Materials · CN · Market cap 2.6B CNY
Fair value as of: Aug 11, 2026
From 25 valuation models · updated today
Share price +12.8% over the past month.
A solid business, but screening 69% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥7.65). The favourable scenario is already priced in.
- Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 11, 2026.
How to read this chart
59‑month range ¥9.81 – ¥31.37 · fair‑value band ¥4.59 – ¥7.65 · the ¥19.60 price screens above the ¥6.12 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 11, 2026.
Analysis
Shaanxi Meibang Pharmaceutical Group (605033) currently trades at ¥19.60, while our model-based Fair Value estimate is ¥6.12, implying the stock looks roughly 68.8% overvalued today. The Quality Score stands at 56/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Shaanxi Meibang Pharmaceutical Group generated revenue of 959M CNY at a net margin of 5.7%. Revenue grew 16.2% year over year. It earns a return on equity of 4.6%. The balance sheet holds a net cash position of 196M CNY. Fundamentals as of Aug 11, 2026
Our scenario range runs from ¥4.59 (bear case) to ¥7.65 (bull case); at ¥19.60, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -13% fair-value upside, at -69%, 605033 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: DCF Models (¥8.25) versus Dividend Discount (¥2.70). Highest evidence: Growth DCF (80).
Notify me when 605033 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 35
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shaanxi Meibang Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research and development, production, sale, and agricultural technology promotion, and service of pesticide products in China and internationally.
Full company description
Shaanxi Meibang Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research and development, production, sale, and agricultural technology promotion, and service of pesticide products in China and internationally. The company offers pesticides, fungicides, herbicides, plant growth regulators, fertilizers, and microbial fertilizers. It is also involved in sale of agricultural machinery. The company was founded in 1998 and is headquartered in Xi'an, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shaanxi Meibang Pharmaceutical Group reported revenue of ¥912M in FY2025 versus ¥842M in FY2021, a compound +2.0%/yr. Reported net income was ¥48.7M in FY2025, compounding −21.1%/yr from FY2021.
605033 screens 69% overvalued. Compare with Corteva, Inc →
Peer Group
Agricultural Inputs · 179 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Agricultural Inputs median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate (as of Aug 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Corteva, Inc CTVA | $86.07 | $27.81 | -68% |
| Nutrien Ltd NTR | C$94.23 | C$81.69 | -13% |
| Qinghai Salt Lake Industry Co 000792 | ¥24.93 | ¥21.26 | -15% |
| CF Industries Holdings CF | $119.19 | $161.00 | +35% |
| SABIC Agri-Nutrients Company 2020 | 122.90 SAR | 127.31 SAR | +4% |
| Yara International ASA YAR | kr 451.30 | kr 67.25 | -85% |
| Yunnan Yuntianhua Co 600096 | ¥30.17 | ¥42.12 | +40% |
| Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893 | ¥42.59 | ¥38.01 | -11% |
| Coromandel International Limited COROMANDEL | ₹2,034 | ₹1,129 | -44% |
| UPL Limited UPL | ₹594.75 | ₹387.06 | -35% |
Compare Shaanxi Meibang Pharmaceutical Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Shaanxi Meibang Pharmaceutical Group (605033) overvalued or undervalued?
What is the fair value of 605033?
What is the quality score of 605033?
What is the revenue of Shaanxi Meibang Pharmaceutical Group (605033)?
What is the net profit margin of 605033?
Does Shaanxi Meibang Pharmaceutical Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shaanxi Meibang Pharmaceutical Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.